Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The JV will research, develop, produce and commercialize human-use vaccines. Sinovac will contribute its expertise and experience in developing and commercializing world-class vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.
Governor Edward G. Rendell today announced that 100,000 Pennsylvanians at-risk for the H1N1 flu were vaccinated during the weekend at public health clinics held by the Department of Health and local health departments.
The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which vaccinations will be employed.
Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing Prodesse's ProParaflu+(TM) assay, a molecular test that detects and differentiates parainfluenza 1, 2 and 3 viruses, which cause lower respiratory tract infections.
Representatives of African countries are meeting in Abuja this week to discuss the procurement and distribution of the H1N1 (swine flu) vaccine, the Daily Trust/allAfrica.com reports (Rabiu, 11/23).
Allied Healthcare International Inc., a leading provider of flexible healthcare staffing services in the United Kingdom, has issued financial results for its fiscal 2009 fourth quarter and year-end.
Hillenbrand reported net revenues of $153.1 million for the fourth quarter of 2009, which ended Sept. 30, 2009, a $5.7 million (3.6 percent) decline from the same period in fiscal 2008. The company posted net income of $22.6 million, a $3.4 million (17.7 percent) increase from last year.
The only swine vaccine available for the H1N1 virus has been sent to vaccinate a swine herd infected with the virus. The vaccination marks the first time vaccine has been sent to a swine herd diagnosed with the pandemic flu.
The H1N1 (swine flu) virus appears to be spreading eastward across Europe and Asia, after appearing to have leveled off in the U.S. and some western European countries, the WHO said Friday, Reuters reports.
Reuters: "The pandemic of swine flu may be hitting a peak in the United States, health experts said on Friday. But they stressed that influenza, especially a pandemic, could hit several peaks in a single season. They said weeks or months more of disease could be expected.
NanoViricides, Inc., announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.
At its annual fall meeting, the Ontario Medical Association (OMA) recognized front line health care workers for their hard work and dedication to patient during this unprecedented flu season. The OMA Council, which represents doctors from across the province, overwhelmingly passed a motion to express its thanks to Medical Officers of Health, physicians, nurses, and other health care professionals for their leadership.
Influenza, particularly H1N1, has understandably captured the attention of public health officials, the media and the public. However, an analysis from Children's Hospital Boston, based on patients seen in its emergency department (ED) during several recent flu seasons, shows that another virus - respiratory syncytial virus (RSV) - takes a substantially greater disease toll among young children than does seasonal flu.
The Department of Health today began providing free H1N1 flu shots to members of priority groups that did not have previous access to the vaccine.
For the protection of frontline health care and emergency medical workers at high risk of infection, the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA) today issued a compliance directive to ensure uniform procedures when conducting inspections to identify and minimize or eliminate high to very high risk occupational exposures to the 2009 H1N1 influenza A virus.
Rates of infection by the 2009 H1N1 influenza virus may have peaked in late October, but the pandemic flu virus continues to be a potential source of illness in all age groups, including the elderly, according to a new report by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services.
The deaths of 41 people from six countries who had received the H1N1 (swine flu) vaccine were not directly linked to the vaccine, the WHO said Thursday, the Associated Press/MSNBC reports (11/19).
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.
Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members.
On November 19, 2009, the kick-off meeting for the Euregio-project "EurSafety Health-net" has taken place. EurSafety Health-net is the follow-up of EUREGIO MRSA-net, that, according to the Robert Koch Institute, gained some sort of model character all over the nation when talking about prevention of hospital acquired MRSA infection. Besides the protection against infection, the main goal of this new project is to strengthen the patients' safety on both sides of the border.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.